vs

Side-by-side financial comparison of ROYAL GOLD INC (RGLD) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $375.3M, roughly 1.7× ROYAL GOLD INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 24.9%, a 9.5% gap on every dollar of revenue. On growth, ROYAL GOLD INC posted the faster year-over-year revenue change (85.3% vs 4.8%). Over the past eight quarters, ROYAL GOLD INC's revenue compounded faster (58.8% CAGR vs 4.6%).

Royal Gold Inc. is a leading precious metals streaming and royalty firm that acquires and manages a diversified portfolio of streaming interests, royalties, and equity interests tied to mining projects. Its assets cover gold, silver, and copper production across North America, South America, Africa, and Australia, operating with a low-risk model that avoids direct mining operations.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

RGLD vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.7× larger
RPRX
$622.0M
$375.3M
RGLD
Growing faster (revenue YoY)
RGLD
RGLD
+80.5% gap
RGLD
85.3%
4.8%
RPRX
Higher net margin
RPRX
RPRX
9.5% more per $
RPRX
34.4%
24.9%
RGLD
Faster 2-yr revenue CAGR
RGLD
RGLD
Annualised
RGLD
58.8%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RGLD
RGLD
RPRX
RPRX
Revenue
$375.3M
$622.0M
Net Profit
$93.6M
$214.2M
Gross Margin
64.6%
Operating Margin
56.2%
62.4%
Net Margin
24.9%
34.4%
Revenue YoY
85.3%
4.8%
Net Profit YoY
-12.8%
2.9%
EPS (diluted)
$1.04
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RGLD
RGLD
RPRX
RPRX
Q4 25
$375.3M
$622.0M
Q3 25
$252.1M
$609.3M
Q2 25
$209.6M
$578.7M
Q1 25
$193.4M
$568.2M
Q4 24
$202.6M
$593.6M
Q3 24
$193.8M
$564.7M
Q2 24
$174.1M
$537.3M
Q1 24
$148.9M
$568.0M
Net Profit
RGLD
RGLD
RPRX
RPRX
Q4 25
$93.6M
$214.2M
Q3 25
$126.8M
$288.2M
Q2 25
$132.3M
$30.2M
Q1 25
$113.5M
$238.3M
Q4 24
$107.4M
$208.2M
Q3 24
$96.2M
$544.0M
Q2 24
$81.2M
$102.0M
Q1 24
$47.2M
$4.8M
Gross Margin
RGLD
RGLD
RPRX
RPRX
Q4 25
64.6%
Q3 25
73.6%
Q2 25
72.6%
Q1 25
69.4%
Q4 24
70.3%
Q3 24
66.6%
Q2 24
64.7%
Q1 24
58.4%
Operating Margin
RGLD
RGLD
RPRX
RPRX
Q4 25
56.2%
62.4%
Q3 25
64.4%
70.1%
Q2 25
67.7%
36.3%
Q1 25
63.6%
94.0%
Q4 24
65.9%
60.9%
Q3 24
61.3%
Q2 24
58.6%
50.2%
Q1 24
50.7%
-13.0%
Net Margin
RGLD
RGLD
RPRX
RPRX
Q4 25
24.9%
34.4%
Q3 25
50.3%
47.3%
Q2 25
63.1%
5.2%
Q1 25
58.7%
41.9%
Q4 24
53.0%
35.1%
Q3 24
49.7%
96.3%
Q2 24
46.6%
19.0%
Q1 24
31.7%
0.8%
EPS (diluted)
RGLD
RGLD
RPRX
RPRX
Q4 25
$1.04
$0.49
Q3 25
$1.92
$0.67
Q2 25
$2.01
$0.07
Q1 25
$1.72
$0.55
Q4 24
$1.63
$0.46
Q3 24
$1.46
$1.21
Q2 24
$1.23
$0.23
Q1 24
$0.72
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RGLD
RGLD
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$233.7M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$7.2B
$9.7B
Total Assets
$9.5B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RGLD
RGLD
RPRX
RPRX
Q4 25
$233.7M
$618.7M
Q3 25
$172.8M
$938.9M
Q2 25
$248.2M
$631.9M
Q1 25
$240.8M
$1.1B
Q4 24
$195.5M
$929.0M
Q3 24
$127.9M
$950.1M
Q2 24
$74.2M
$1.8B
Q1 24
$137.9M
$843.0M
Total Debt
RGLD
RGLD
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$0
$7.6B
Q2 24
$50.0M
$7.6B
Q1 24
$6.1B
Stockholders' Equity
RGLD
RGLD
RPRX
RPRX
Q4 25
$7.2B
$9.7B
Q3 25
$3.4B
$9.6B
Q2 25
$3.3B
$9.5B
Q1 25
$3.2B
$9.8B
Q4 24
$3.1B
$10.3B
Q3 24
$3.0B
$10.3B
Q2 24
$3.0B
$9.8B
Q1 24
$2.9B
$9.9B
Total Assets
RGLD
RGLD
RPRX
RPRX
Q4 25
$9.5B
$19.6B
Q3 25
$4.5B
$19.3B
Q2 25
$3.6B
$18.3B
Q1 25
$3.5B
$17.6B
Q4 24
$3.4B
$18.2B
Q3 24
$3.3B
$18.0B
Q2 24
$3.3B
$17.7B
Q1 24
$3.3B
$16.1B
Debt / Equity
RGLD
RGLD
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.00×
0.74×
Q2 24
0.02×
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RGLD
RGLD
RPRX
RPRX
Operating Cash FlowLast quarter
$241.7M
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.58×
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RGLD
RGLD
RPRX
RPRX
Q4 25
$241.7M
$827.1M
Q3 25
$174.0M
$702.6M
Q2 25
$152.8M
$364.0M
Q1 25
$136.4M
$596.1M
Q4 24
$141.1M
$742.5M
Q3 24
$136.7M
$703.6M
Q2 24
$113.5M
$658.2M
Q1 24
$138.3M
$664.6M
Cash Conversion
RGLD
RGLD
RPRX
RPRX
Q4 25
2.58×
3.86×
Q3 25
1.37×
2.44×
Q2 25
1.15×
12.06×
Q1 25
1.20×
2.50×
Q4 24
1.31×
3.57×
Q3 24
1.42×
1.29×
Q2 24
1.40×
6.45×
Q1 24
2.93×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RGLD
RGLD

Gold$216.9M58%
Pueblo Viejo$47.3M13%
Andacollo$32.6M9%
Silver$32.1M9%
Other$27.2M7%
Copper$13.7M4%
Cortez Legacy Zone$5.4M1%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons